Phillip O. Rawlings, Jr., M.D.; Decision and Order, 51982-51983 [2018-22421]
Download as PDF
51982
Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices
(except for exportation), and soliciting
U.S. agents or distributors for, nonvolatile memory device and products
containing same covered by claim 6 of
the ’602 patent.
The Commission has also determined
that the public interest factors
enumerated in section 337(d) and (f) (19
U.S.C. 1337(d) and (f)) do not preclude
issuance of the limited exclusion order
or cease and desist orders. Finally, the
Commission has determined that a bond
in the amount of 100 percent of entered
value for Toshiba flash memory devices,
solid-state drives, USB flash drives, and
microcontroller units; and a bond in the
amount of six percent of entered value
for Toshiba personal computers, multifunction printers, and air conditioners is
required to permit temporary
importation during the period of
Presidential review (19 U.S.C. 1337(j))
of products that are subject to the
remedial orders. The Commission’s
orders and opinion were delivered to
the President and to the United States
Trade Representative on the day of their
issuance.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: October 9, 2018
Katherine Hiner,
Supervisory Attorney.
[FR Doc. 2018–22325 Filed 10–12–18; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
khammond on DSK30JT082PROD with NOTICES
Phillip O. Rawlings, Jr., M.D.; Decision
and Order
On March 8, 2018, the Acting
Assistant Administrator, Diversion
Control Division, Drug Enforcement
Administration (DEA), issued an Order
to Show Cause to Phillip O. Rawlings,
Jr., M.D. (Registrant), of Mobile,
Alabama. The Show Cause Order
proposed the revocation of Registrant’s
DEA Certificate of Registration No.
FR0024997 on the ground that he has
‘‘no state authority to handle controlled
substances.’’ Order to Show Cause,
Government Exhibit (GX) 8, at 1 (citing
21 U.S.C. 824(a)(3)). For the same
reason, the Order also proposed the
denial of any of Registrant’s
‘‘applications for renewal or
modification of such registration and
VerDate Sep<11>2014
21:34 Oct 12, 2018
Jkt 247001
any applications for any other DEA
registrations.’’ Id.
Regarding the Agency’s jurisdiction,
the Show Cause Order alleged that
Registrant holds DEA Certificate of
Registration No. FR0024997, pursuant to
which he is authorized to dispense
controlled substances as a practitioner
in schedules II through V at the
registered address of Providence Family
Physicians, 8833 Cottage Hill Road,
Mobile, Alabama. Id. The Order also
alleged that this registration was set to
expire by its terms on April 30, 2018. Id.
The substantive ground for the
proceeding set forth in the Show Cause
Order is that Registrant is ‘‘currently
without authority to practice medicine
or handle controlled substances in the
State of Alabama, the state in which [he
is] registered with the DEA’’ because
Registrant’s Alabama Medical License
and Alabama Controlled Substances
Certificate have been in ‘‘Inactive-By
Request’’ status since December 31,
2016 . Id. As a consequence, the Order
alleged that ‘‘DEA must revoke your
DEA registration.’’ Id. at 2.
The Show Cause Order notified
Registrant of his right to request a
hearing on the allegations or to submit
a written statement in lieu of a hearing,
the procedures for electing each option,
and the consequences for failing to elect
either option. Id. (citing 21 CFR
1301.43). The Order also notified
Registrant of the opportunity to submit
a corrective action plan. Id. at 2–3
(citing 21 U.S.C. 824(c)(2)(C)).
On April 26, 2018, my office received
the Government’s Second Request for
Final Agency Action (SRFAA) 1
describing Diversion Investigators’
attempts to serve the Show Cause Order
and seeking a final order revoking
Registrant’s registration. SRFAA, at 2, 6.
1 On January 10, 2018, the Government submitted
a Request for Final Agency Action seeking to revoke
Registrant’s same DEA registration based on an
October 31, 2017 Order to Show Cause. GX 6. In
that Request, the Government represented that
Registrant did not request a hearing and ‘‘ha[d] not
otherwise corresponded or communicated with
DEA regarding the Order served on him . . . within
30 days of receipt of the Order.’’ Id. at 1–2.
However, on February 6, 2018, the then-Acting
Administrator issued an Order noting that,
‘‘although the Government is clearly in possession
of information suggesting that Registrant now lives
in California, it has offered no explanation for why
it did not attempt to obtain Registrant’s address
from the Board of Medical Examiners and serve
Registrant at that address.’’ GX 7, at 1. As a result,
the then-Administrator denied the Government’s
Request for Final Agency Action without prejudice.
Id. at 2. See also SRFAA, at 1–2. By that time, the
December 26, 2017 hearing date listed in the 2017
Show Cause Order had passed. SRFAA, at 2 n.1. As
a result, the Agency issued the pending Show Cause
Order on March 8, 2018, with a new hearing date
of April 24, 2018. Id.; GX 8, at 1. It is this new Show
Cause Order for which the Government now seeks
final agency action.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
The Government also submitted a
Certification of Registration History,
which was sworn to on December 28,
2017 by the Associate Chief of the
Registration and Program Support
Section. GX 1. In that Certification, she
stated that DEA Registration No.
FR0024997 ‘‘expires on April 30, 2018.’’
Id. at 1. The Associate Chief further
stated that ‘‘Phillip O. Rawlings, Jr.,
M.D., has no other pending or valid
DEA registration(s) in Alabama.’’ Id.
According to the Agency’s current
registration records for Registrant, of
which I take official notice,2 DEA
Registration No. FR0024997 expired on
April 30, 2018, and he has not
submitted an application to renew his
registration or for any other registration
in the State of Alabama. Thus, I find
that Registrant’s registration expired on
April 30, 2018, and that there is no
application upon which to act.3
DEA has long held that ‘‘ ‘if a
registrant has not submitted a timely
renewal application prior to the
expiration date, then the registration
expires and there is nothing to revoke.’ ’’
Donald Brooks Reece II, M.D., 77 FR
35054, 35055 (2012) (quoting Ronald J.
Riegel, 63 FR 67312, 67133 (1998)); see
also Greg N. Rampey, D.O., 83 FR
2 Under the Administrative Procedure Act (APA),
an agency ‘‘may take official notice of facts at any
stage in a proceeding—even in the final decision.’’
U.S. Dept. of Justice, Attorney General’s Manual on
the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). In accordance
with the APA and DEA’s regulations, Registrant is
‘‘entitled on timely request to an opportunity to
show to the contrary.’’ 5 U.S.C. 556(e); see also 21
CFR 1316.59(e). To allow Registrant the opportunity
to refute the facts of which I take official notice,
Registrant may file a motion for reconsideration
within 15 calendar days of service of this order
which shall commence on the date this order is
mailed.
3 As already noted, my Office received the
Government’s Second Request for Final Agency
Action on April 26, 2018. This filing arrived in my
office too late for me to issue a final decision and
order before the registration would expire on April
30, 2018. DEA regulation 21 CFR 1316.67 requires
that I issue a final order that takes effect not less
than 30 days from the date of publication in the
Federal Register unless the public interest
necessitates an earlier effective date. The record
before me fails to include facts supporting a finding
that ‘‘the public interest in the matter necessitates
an earlier effective date.’’ 21 CFR 1316.67. Thus,
even if I had submitted a final order in this case
to the Federal Register on the same day (April 26,
2018) that my office received the SRFAA to revoke
Registrant’s registration, I could not have issued an
order that would have taken effect by April 30, 2018
because the Federal Register would not have been
able to publish it 30 days before the registration’s
April 30, 2018 expiration. And as the Agency has
previously noted, there is no point in issuing a
ruling on a Show Cause Order where, as here, that
ruling would constitute an advisory opinion subject
to vacation on judicial review. See, e.g., Josip Pasic,
M.D., 82 FR 24146, 24147 (2017) (‘‘As the requested
factual findings and legal conclusions would be
subject to vacation on judicial review, there is no
point in making them.’’).
E:\FR\FM\15OCN1.SGM
15OCN1
51983
Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices
42696, 42697 (2018). ‘‘Moreover, in the
absence of an application (whether
timely filed or not), there is nothing to
act upon.’’ Reece, 77 FR at 35055,
Rampey, 83 FR at 42697. Accordingly,
because Registrant has allowed his
registration to expire and has not filed
an application to renew his registration
or for any other registration in Alabama,
this case is now moot and will be
dismissed.
Order
Pursuant to 28 CFR 0.100(b) and the
authority thus vested in me by 21 U.S.C.
824(a), I order that the Order to Show
Cause issued to Phillip O. Rawlings, Jr.,
M.D., be, and it hereby is, dismissed.
This Order is effective immediately.
[FR Doc. 2018–22421 Filed 10–12–18; 8:45 am]
BILLING CODE 4410–09–P
The
company listed below applied to be
registered as an importer of various
basic classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
ACTION:
registration by the Drug Enforcement
Administration (DEA) as importers of
various classes of schedule I or II
controlled substances.
Notice of registration.
Registrant listed below have
applied for and been granted
SUMMARY:
Company
FR Docket
Galephar Pharmaceutical Research Inc .................................
83 FR 37525 ..........................................................................
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the
registration of the listed registrant to
import the applicable basic classes of
schedule I or II controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substance to
the above listed company.
Dated: September 24, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–22420 Filed 10–12–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
khammond on DSK30JT082PROD with NOTICES
Dated: September 26, 2018.
Uttam Dhillon,
Acting Administrator.
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Cambrex High Point, Inc.
ACTION:
Notice of application.
VerDate Sep<11>2014
21:34 Oct 12, 2018
Jkt 247001
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before November 14, 2018. Such
persons may also file a written request
for a hearing on the application on or
before November 14, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
DATES:
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Published
August 1, 2018.
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.34(a), this is notice that on July 16,
2018, Cambrex High Point Inc., 4180
Mendenhall Oaks Parkway, High Point,
North Carolina 27265–8017 applied to
be registered as an importer of the
following basic classes of controlled
substances:
Controlled
substance
Drug
code
Schedule
Amphetamine ...................
Codeine ............................
Oxymorphone ...................
Noroxymorphone ..............
1100
9050
9652
9668
II
II
II
II
The company plans to manufacture
the above listed controlled substances in
bulk for distribution to its customers.
Dated: October 1, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018–22416 Filed 10–12–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Specgx, LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
DATES:
E:\FR\FM\15OCN1.SGM
15OCN1
Agencies
[Federal Register Volume 83, Number 199 (Monday, October 15, 2018)]
[Notices]
[Pages 51982-51983]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22421]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Phillip O. Rawlings, Jr., M.D.; Decision and Order
On March 8, 2018, the Acting Assistant Administrator, Diversion
Control Division, Drug Enforcement Administration (DEA), issued an
Order to Show Cause to Phillip O. Rawlings, Jr., M.D. (Registrant), of
Mobile, Alabama. The Show Cause Order proposed the revocation of
Registrant's DEA Certificate of Registration No. FR0024997 on the
ground that he has ``no state authority to handle controlled
substances.'' Order to Show Cause, Government Exhibit (GX) 8, at 1
(citing 21 U.S.C. 824(a)(3)). For the same reason, the Order also
proposed the denial of any of Registrant's ``applications for renewal
or modification of such registration and any applications for any other
DEA registrations.'' Id.
Regarding the Agency's jurisdiction, the Show Cause Order alleged
that Registrant holds DEA Certificate of Registration No. FR0024997,
pursuant to which he is authorized to dispense controlled substances as
a practitioner in schedules II through V at the registered address of
Providence Family Physicians, 8833 Cottage Hill Road, Mobile, Alabama.
Id. The Order also alleged that this registration was set to expire by
its terms on April 30, 2018. Id.
The substantive ground for the proceeding set forth in the Show
Cause Order is that Registrant is ``currently without authority to
practice medicine or handle controlled substances in the State of
Alabama, the state in which [he is] registered with the DEA'' because
Registrant's Alabama Medical License and Alabama Controlled Substances
Certificate have been in ``Inactive-By Request'' status since December
31, 2016 . Id. As a consequence, the Order alleged that ``DEA must
revoke your DEA registration.'' Id. at 2.
The Show Cause Order notified Registrant of his right to request a
hearing on the allegations or to submit a written statement in lieu of
a hearing, the procedures for electing each option, and the
consequences for failing to elect either option. Id. (citing 21 CFR
1301.43). The Order also notified Registrant of the opportunity to
submit a corrective action plan. Id. at 2-3 (citing 21 U.S.C.
824(c)(2)(C)).
On April 26, 2018, my office received the Government's Second
Request for Final Agency Action (SRFAA) \1\ describing Diversion
Investigators' attempts to serve the Show Cause Order and seeking a
final order revoking Registrant's registration. SRFAA, at 2, 6. The
Government also submitted a Certification of Registration History,
which was sworn to on December 28, 2017 by the Associate Chief of the
Registration and Program Support Section. GX 1. In that Certification,
she stated that DEA Registration No. FR0024997 ``expires on April 30,
2018.'' Id. at 1. The Associate Chief further stated that ``Phillip O.
Rawlings, Jr., M.D., has no other pending or valid DEA registration(s)
in Alabama.'' Id. According to the Agency's current registration
records for Registrant, of which I take official notice,\2\ DEA
Registration No. FR0024997 expired on April 30, 2018, and he has not
submitted an application to renew his registration or for any other
registration in the State of Alabama. Thus, I find that Registrant's
registration expired on April 30, 2018, and that there is no
application upon which to act.\3\
---------------------------------------------------------------------------
\1\ On January 10, 2018, the Government submitted a Request for
Final Agency Action seeking to revoke Registrant's same DEA
registration based on an October 31, 2017 Order to Show Cause. GX 6.
In that Request, the Government represented that Registrant did not
request a hearing and ``ha[d] not otherwise corresponded or
communicated with DEA regarding the Order served on him . . . within
30 days of receipt of the Order.'' Id. at 1-2. However, on February
6, 2018, the then-Acting Administrator issued an Order noting that,
``although the Government is clearly in possession of information
suggesting that Registrant now lives in California, it has offered
no explanation for why it did not attempt to obtain Registrant's
address from the Board of Medical Examiners and serve Registrant at
that address.'' GX 7, at 1. As a result, the then-Administrator
denied the Government's Request for Final Agency Action without
prejudice. Id. at 2. See also SRFAA, at 1-2. By that time, the
December 26, 2017 hearing date listed in the 2017 Show Cause Order
had passed. SRFAA, at 2 n.1. As a result, the Agency issued the
pending Show Cause Order on March 8, 2018, with a new hearing date
of April 24, 2018. Id.; GX 8, at 1. It is this new Show Cause Order
for which the Government now seeks final agency action.
\2\ Under the Administrative Procedure Act (APA), an agency
``may take official notice of facts at any stage in a proceeding--
even in the final decision.'' U.S. Dept. of Justice, Attorney
General's Manual on the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). In accordance with the APA and
DEA's regulations, Registrant is ``entitled on timely request to an
opportunity to show to the contrary.'' 5 U.S.C. 556(e); see also 21
CFR 1316.59(e). To allow Registrant the opportunity to refute the
facts of which I take official notice, Registrant may file a motion
for reconsideration within 15 calendar days of service of this order
which shall commence on the date this order is mailed.
\3\ As already noted, my Office received the Government's Second
Request for Final Agency Action on April 26, 2018. This filing
arrived in my office too late for me to issue a final decision and
order before the registration would expire on April 30, 2018. DEA
regulation 21 CFR 1316.67 requires that I issue a final order that
takes effect not less than 30 days from the date of publication in
the Federal Register unless the public interest necessitates an
earlier effective date. The record before me fails to include facts
supporting a finding that ``the public interest in the matter
necessitates an earlier effective date.'' 21 CFR 1316.67. Thus, even
if I had submitted a final order in this case to the Federal
Register on the same day (April 26, 2018) that my office received
the SRFAA to revoke Registrant's registration, I could not have
issued an order that would have taken effect by April 30, 2018
because the Federal Register would not have been able to publish it
30 days before the registration's April 30, 2018 expiration. And as
the Agency has previously noted, there is no point in issuing a
ruling on a Show Cause Order where, as here, that ruling would
constitute an advisory opinion subject to vacation on judicial
review. See, e.g., Josip Pasic, M.D., 82 FR 24146, 24147 (2017)
(``As the requested factual findings and legal conclusions would be
subject to vacation on judicial review, there is no point in making
them.'').
---------------------------------------------------------------------------
DEA has long held that `` `if a registrant has not submitted a
timely renewal application prior to the expiration date, then the
registration expires and there is nothing to revoke.' '' Donald Brooks
Reece II, M.D., 77 FR 35054, 35055 (2012) (quoting Ronald J. Riegel, 63
FR 67312, 67133 (1998)); see also Greg N. Rampey, D.O., 83 FR
[[Page 51983]]
42696, 42697 (2018). ``Moreover, in the absence of an application
(whether timely filed or not), there is nothing to act upon.'' Reece,
77 FR at 35055, Rampey, 83 FR at 42697. Accordingly, because Registrant
has allowed his registration to expire and has not filed an application
to renew his registration or for any other registration in Alabama,
this case is now moot and will be dismissed.
Order
Pursuant to 28 CFR 0.100(b) and the authority thus vested in me by
21 U.S.C. 824(a), I order that the Order to Show Cause issued to
Phillip O. Rawlings, Jr., M.D., be, and it hereby is, dismissed. This
Order is effective immediately.
Dated: September 26, 2018.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2018-22421 Filed 10-12-18; 8:45 am]
BILLING CODE 4410-09-P